Navigation Links
Chiltern Appoints Steve Albrecht to Support Further Expansion in Late Phase
Date:10/8/2007

LONDON, Oct. 9 /PRNewswire/ -- Chiltern, a leading global clinical research organization, has announced the appointment of Steve Albrecht to the role of Director, Business Operations, Late Phase. Steve Albrecht brings over 20 years of CRO industry experience to his new appointment; previously he held executive management positions with other major CROs and recently Registrat in late phase development.

Mr. Albrecht will be providing leadership for the development, implementation and execution of Chiltern's Late Phase strategies.

"I am delighted to join the current excellent staff at Chiltern," said Steve "and I look forward to further developing the Late Phase division in order to provide our sponsors with the best available options for the conduct of their Phase IIIb/IV studies. Post marketing studies pose an excellent opportunity to combine the knowledge gained in early phase development with well-designed and implemented late phase programs. Today, FDA and the pharmaceutical industry are mandating an ever-increasing number of post-marketing trials to follow products in a real-world setting. These studies require high quality standards yielding high quality data."

"I am delighted that Steve has joined Chiltern," commented James Esinhart, Executive Vice President, Biometrics & Late Phase. "Steve's strong background in Late Phase will add strength to our group and provide sponsors with services in the design and execution of both commercial programs and risk management programs for their marketed products."

About Chiltern:

Established in 1982, Chiltern is a leading global Contract Research Organization with extensive experience conducting and staffing international Phase I to Phase IV clinical trials across a broad therapeutic range for a wide variety of clients. Chiltern employs more than 1000 people with 18 offices across the United States, Europe and in India. Chiltern provides services including Early Phase, Global Clinical Development, Late Phase, Biometrics, Medical and Regulatory Affairs and Resourcing Solutions.

For More Information Contact:

Catherine Lemercier Richard Baptista

Chiltern International, Inc. Chiltern International Ltd.

2111 Palomar Airport Road 171 Bath Road

Suite 200 Slough

Carlsbad Berkshire

CA 92011 SL1 4AA

USA UNITED KINGDOM

Tel: 1 (760) 707 5025 Tel: 44 (0) 1753 512 000

Fax: 1 (760) 707 5022 Fax: 44 (0) 1753 511 116

Email: Catherine.Lemercier@chiltern.com Email:

Richard.Baptista@chiltern.com

Chiltern: Understanding


'/>"/>
SOURCE Chiltern
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Steve Tyler Tells All About His Beauty Regime
2. Prince Charles lends support to Alternative Medicine
3. Support therapy helps breast cancer patients
4. Evidence supporting H.pylori eradication
5. Further support for use of statins in Alzheimer’s disease
6. Toxin injections support stroke associated spasticity
7. Support for patients with Leg Pain
8. Vitamin E supports Female Hearts
9. Injection supports Heart Devices
10. Modified antibiotic may support fight cancer
11. WHO To Support Public Health Threats
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... WI (PRWEB) , ... March 27, 2017 , ... ... new patients for custom smile makeovers without requiring a referral. Trimble ... orthodontics, gum disease treatment, cosmetic dentistry and dental implants. Whether patients have discolored, ...
(Date:3/27/2017)... ... 2017 , ... This is the second major release since ... 2014. It is the culmination of collaborative efforts by members of the OSEHRA ... Member Zato Health co-funded the ONC certification and provided key technical support throughout ...
(Date:3/27/2017)... MA (PRWEB) , ... March 27, 2017 , ... ... Group, the organization behind the New England Journal of Medicine and NEJM Journal ... NEJM Knowledge+ Pediatrics Board Review was created by a panel of pediatricians from ...
(Date:3/27/2017)... ... March 27, 2017 , ... Osteitis pubis may ... of groin injury, it occurs when the muscles around the pelvis become inflamed. ... around the lower torso, as well as accompanying tenderness and weakness. Without proper ...
(Date:3/27/2017)... Atlanta, Georgia (PRWEB) , ... March 27, 2017 ... ... pleased to announce that for a second year in a row; they are ... leading healthcare designers in the industry voted on the award at Design Connections ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... , March 27, 2017 /PRNewswire/ - INVICTUS MD STRATEGIES ... FRA: 8IS) Invictus MD is pleased to announce it ... for trading on the TSX Venture Exchange.  ... follows a year of significant achievements for Invictus-MD. Some ... test crops at AB Laboratories Inc. ("AB Labs"), a ...
(Date:3/27/2017)... -- The global clinical chemistry analyzers ... 2025, according to a new study by Grand View ... anticipated to be responsible for the high urgency to ... for growth during the forecast period. In addition, growing ... susceptible to chronic diseases, is presumed to impel the ...
(Date:3/27/2017)...  Twist Bioscience, a company accelerating science and innovation ... raised an additional $33 million. To date, Twist Bioscience ... "It is an exciting time to be leading ... to deliver industry-leading gene volume to our customers, enabling ... Leproust, Ph.D., CEO of Twist Bioscience. "We welcome the ...
Breaking Medicine Technology: